We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Grows on New Products, Currency Woe Ails
Read MoreHide Full Article
On Oct 9, 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) .
Over the past three months, Boston Scientific has been trading above the broader industry. The stock has improved 7% compared with the broader industry's 4.7% gain during the period.
Among the recent upsides, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify the European structural heart business. We are also encouraged by the company securing multiple product approvals both in domestic as well as overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems.
Additionally, the market holds optimism on the stock, following the company’s recent release of an outline on sustained growth strategy, focusing on planned expansion in new markets and consolidating product lines across all business segments. The company particularly plans to launch products into high-growth adjacent markets with a strong potential to reap an incremental $13 billion in market opportunity by 2020.
While adverse foreign exchange continues to pose challenges, we are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. It is important to note that last quarter, foreign exchange headwind affected the company’s top line by $23 million and adjusted gross margin by 50 basis points.
Also, a dull defibrillator sale within its core Cardiac Rhythm Management (CRM) continues to remain a drag for overall growth. The woes of a challenging economy and a competitive landscape persistently burden the stock.
However, given the company’s bullish second-quarter 2017 results and several recent developments, we find quite a few positive factors to rely on. The company is leaving no stone unturned to reinforce its core businesses and invest more in global markets.
Zacks Rank & Key Picks
Boston Scientific carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 39% over the last six months.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 21.4% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has surged 35.8% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific Grows on New Products, Currency Woe Ails
On Oct 9, 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) .
Over the past three months, Boston Scientific has been trading above the broader industry. The stock has improved 7% compared with the broader industry's 4.7% gain during the period.
Among the recent upsides, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify the European structural heart business. We are also encouraged by the company securing multiple product approvals both in domestic as well as overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems.
Additionally, the market holds optimism on the stock, following the company’s recent release of an outline on sustained growth strategy, focusing on planned expansion in new markets and consolidating product lines across all business segments. The company particularly plans to launch products into high-growth adjacent markets with a strong potential to reap an incremental $13 billion in market opportunity by 2020.
Boston Scientific Corporation Price and Consensus
Boston Scientific Corporation Price and Consensus | Boston Scientific Corporation Quote
While adverse foreign exchange continues to pose challenges, we are concerned with the company’s recall of one of its prime products, Lotus range of heart devices. It is important to note that last quarter, foreign exchange headwind affected the company’s top line by $23 million and adjusted gross margin by 50 basis points.
Also, a dull defibrillator sale within its core Cardiac Rhythm Management (CRM) continues to remain a drag for overall growth. The woes of a challenging economy and a competitive landscape persistently burden the stock.
However, given the company’s bullish second-quarter 2017 results and several recent developments, we find quite a few positive factors to rely on. The company is leaving no stone unturned to reinforce its core businesses and invest more in global markets.
Zacks Rank & Key Picks
Boston Scientific carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Orthofix International sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has rallied roughly 39% over the last six months.
Thermo Fisher has a long-term expected earnings growth rate of 16.3%. The stock has gained 21.4% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has surged 35.8% last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>